Biocon Ltd.
BIOCON · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹450.08.
Piotroski F-score 6/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%1.1%
- ✓Low debt (D/E < 0.5)0.42x
- ✕Positive free cash flow
- ✕Revenue growth > 10%2%
- ✕Earnings growing-73%
- ✕Net margin ≥ 10%2.3%
- ✕Current ratio > 1.51.22
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✕Altman Z in safe zoneZ 2.24
- ✕Piotroski ≥ 76/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Weaknesses
- •Low return on equity (1.1%).
Opportunities
- •Trades ~35% below our estimated fair value.
Threats
- •Earnings contracting year on year.
About Biocon Ltd.
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimi
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.